The actual match rate is significantly higher than the 10 percent rate the researchers anticipated they would see when the study began in 2017.
The method's developers believe that clinicians could use approach to predict how high-grade, serous ovarian cancer patients will respond to chemotherapy.
The company formerly known as TransMed Systems looks to bring "clarity and transparency" to the emerging field of precision oncology and in patient-trial matching.
The firm hopes for a decision from the FDA later this year for its breast cancer drug candidate alpelisib, following results from a late-stage trial.
In the Phase I/IB study, only patients with NTRK or ROS1 fusions, or an ALK fusion or mutation responded to entrectinib, while patients without these tumor markers didn’t respond.
Novartis' alpelisib is the first PI3K inhibitor approved for advanced or metastatic breast cancer patients who harbor PIK3CA mutations.